Author: Mansour, Eli; Palma, Andre C.; Ulaf, Raisa G.; Ribeiro, Luciana C.; Bernardes, Ana Flavia; Nunes, Thyago A.; Agrela, Marcus V.; Bombassaro, Bruna; Monfort-Pires, Milena; Camargo, Rafael L.; Araujo, Eliana P.; Brunetti, Natalia S.; Farias, Alessandro S.; Falcão, Antônio LuÃs E.; Santos, Thiago Martins; Trabasso, Plinio; Dertkigil, Rachel P.; Dertkigil, Sergio S.; Moretti, Maria Luiza; Velloso, Licio A.
Title: Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19 Cord-id: 7qfitjqe Document date: 2021_2_16
ID: 7qfitjqe
Snippet: Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major pathological finding in autopsies explaining O(2) diffusion failure and hypoxemia. Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity. SARS-CoV-2 enters cells employing angiotensin-converting enzyme 2 (ACE2) as a receptor, which is highly express
Document: Background: Coronavirus disease 19 (COVID-19) can develop into a severe respiratory syndrome that results in up to 40% mortality. Acute lung inflammatory edema is a major pathological finding in autopsies explaining O(2) diffusion failure and hypoxemia. Only dexamethasone has been shown to reduce mortality in severe cases, further supporting a role for inflammation in disease severity. SARS-CoV-2 enters cells employing angiotensin-converting enzyme 2 (ACE2) as a receptor, which is highly expressed in lung alveolar cells. ACE2 is one of the components of the cellular machinery that inactivates the potent inflammatory agent bradykinin, and SARS-CoV-2 infection could interfere with the catalytic activity of ACE2, leading to the accumulation of bradykinin. Methods: In this case control study, we tested two pharmacological inhibitors of the kinin–kallikrein system that are currently approved for the treatment of hereditary angioedema, icatibant, and inhibitor of C1 esterase/kallikrein, in a group of 30 patients with severe COVID-19. Results: Neither icatibant nor inhibitor of C1 esterase/kallikrein resulted in changes in time to clinical improvement. However, both compounds were safe and promoted the significant improvement of lung computed tomography scores and increased blood eosinophils, which are indicators of disease recovery. Conclusions: In this small cohort, we found evidence for safety and a beneficial role of pharmacological inhibition of the kinin–kallikrein system in two markers that indicate improved disease recovery.
Search related documents:
Co phrase search for related documents- acute phase and liver disease: 1, 2, 3, 4, 5, 6
- acute phase and long term respiratory function: 1
- acute phase and lopinavir ritonavir: 1, 2, 3, 4, 5
- acute phase and lopinavir trial: 1
- acute phase and low expression: 1, 2, 3
- acute phase and lung autopsy: 1, 2, 3
- acute phase and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20
- acute phase and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute phase and lung lesion: 1
- acute phase and lung recovery: 1, 2, 3, 4
- acute phase and lung score: 1, 2, 3, 4, 5, 6, 7
- acute respiratory failure and admission severity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- acute respiratory failure and liver disease: 1, 2, 3, 4, 5, 6, 7, 8
- acute respiratory failure and lopinavir ritonavir: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- acute respiratory failure and low expression: 1, 2, 3
- acute respiratory failure and lung autopsy: 1, 2, 3, 4
- acute respiratory failure and lung damage: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23
- acute respiratory failure and lung inflammation: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16
- acute respiratory failure and lung lesion: 1, 2
Co phrase search for related documents, hyperlinks ordered by date